Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2024. Filed Feb 19, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 19, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
Our primary operations are conducted at the leased facilities summarized in the below table. In 2023, we completed the construction of our gene therapy manufacturing facility located in Bedford, Massachusetts. We believe our facilities are adequate and suitable for our current needs and that we will be able to obtain new or additional leased space in the future when necessary.
| Property Location | Use | Lease Expiration Date |
|---|---|---|
| Novato, California | Headquarters and office | December 2026 |
| Novato, California | Laboratory and office | October 2028 |
| Brisbane, California | Office | June 2026 |
| Somerville, Massachusetts | Laboratory and office | January 2030 |
| Woburn, Massachusetts | Laboratory and office | April 2028 |
| Woburn, Massachusetts | Laboratory and office | October 2026 |
| Bedford, Massachusetts | Manufacturing facility | Owned property |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.